MorphoSys AG

General information
MorphoSys AG
Semmelweisstr. 7
82152 Planegg, Bavaria

Contact person: Julia Neugebauer, Senior Director Investor Relations
Company main phone: +49 (89) 899270
Company main fax:  +49 (89) 89927222
Year founded:1992
Source of foundation:Independent foundation
No. of employees: Worldwide:  648
Corporate description / mission:
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases, with a focus on cancer. The company's product include Tafasitamab (MOR208, formerly Xmab®5574) an investigational monoclonal antibody directed against the antigen CD19 which is broadly expressed on the surface of B cells.
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 1999
Remarks on ownership / listings
MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts.
  • Biotechnology - Therapeutics and Diagnostics
  • Anti-infectives
  • Antibodies
  • Immunotherapy
  • Peptides
Primary therapeutic areas:
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Diseases of the nervous system / neurology
  • Endocrine, nutritional and metabolic diseases / endocrinology
  • Musculoskeletal system and connective tissue / Orthopedics
  • Neoplasms / cancer / oncology
  • Skin and subcutaneous tissue / dermatology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Business model:
  • Manufacturer
  • R&D
  • Supplier / Distributor
Customer segments:
  • Hospitals
  • Large biotech & big pharma
  • Small biotech
Summary Products / Services / Technologies
Number of Biotech Products
Phase I:26
Phase II:34
Phase III:16
On the market:2
Description of products:
CPI-0209, etc.
Special IP situation:
MorphoSys has built a strong IP portfolio around its proprietary technology, HuCAL.
Technology used:
HuCAL (Human Combinatorial Antibody Library) technology
Financing details
Fiscal year (end of) 2021
Revenues:EUR 179.61M
R&D expenses:EUR 225.21M
No. of shares:34'153'400
Market cap. / valuation:EUR 767.82M
Collaborations & Clients
Partnering strategy / collaborations:
Ultragenyx and Mereo Biopharma etc